Efficacy, safety and exercise endurance primary endpoints all met
TOKYO, April 2, 2012 /CNW/ – Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), confirms the information released today by Novartis that the first three QVA149 Phase III studies in the treatment of chronic obstructive pulmonary disease (COPD) all met their primary endpoints. The SHINE, BRIGHT and ENLIGHTEN studies, which are part of the IGNITE program demonstrate the potential of QVA149 in the treatment of COPD. Read the rest of this entry »
kakonged
